Justin Boike, MD
Hepatology · Chicago, ILNPI 1497014294
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,672 of the $24,202 with a category attached, or 73.0%. Novo Nordisk accounts for 77.9% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $22,556, more than ten times the $1,180 reported in 2021.
Across 27 payments — averaging $896.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$19K
- W. L. Gore & Associates, Inc.$4K
- Fujifilm Healthcare Americas Corporation$1K
- Cook Medical LLC$168
- Mallinckrodt Hospital Products Inc.$162
- Phathom Pharmaceuticals, Inc.$142
- plus $95 from 2 others
Across 11 payments — averaging $7118.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Madrigal Pharmaceuticals$78K
What the payments were for
- Consulting fees$4,53019%
- Speaking & faculty fees$17,67273%
- Travel & lodging$6983%
- Food & beverage$1,3015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $18,842 |
| W. L. Gore & Associates, Inc. | 4 | $3,662 |
| Fujifilm Healthcare Americas Corporation | 3 | $1,131 |
| Cook Medical LLC | 1 | $168 |
| Mallinckrodt Hospital Products Inc. | 2 | $162 |
| Phathom Pharmaceuticals, Inc. | 1 | $142 |
| Gilead | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,202 in reported general payments places this provider in the 70th percentile of 21 hepatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 11 | $252,045 |
| XifaxanRifaximin | 44 | $153,598 |
| VemlidyTenofovir Alafenamide | 24 | $40,009 |
| Tacrolimus | 167 | $28,821 |
| Envarsus XrTacrolimus | 12 | $19,631 |
| Entecavir | 43 | $19,578 |
| Ursodiol | 89 | $15,599 |
| Cyclosporine ModifiedCyclosporine, Modified | 22 | $5,159 |
| Mycophenolate Mofetil | 49 | $2,982 |
| Nifedipine ErNifedipine | 20 | $1,414 |
| Azathioprine | 19 | $1,041 |
| Midodrine Hcl | 15 | $924 |
| Lactulose | 21 | $896 |
| Pantoprazole Sodium | 54 | $827 |
| Carvedilol | 87 | $547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $61 | $292,05535 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $34 | $153,59844 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 21 hepatology providers in Illinois.
Other hepatology in Chicago
- Sean KoppeChicago$152K
- Veronica LoyChicago$78K
- Amanda CheungChicago$64K
- Daniel GangerChicago$58K
- Christopher MooreChicago$57K
- Andres DuarteChicago$11K
- Anna PatelChicago$6K
- Sarang ThakerChicago$6K
- Sheila EswaranChicago$1K
- Sonu DhillonChicago$995
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.